期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

喹唑啉结构的多靶点酪氨酸激酶抑制剂研究进展 被引量：2

下载PDF
导出
摘要 随着肿瘤机制和抗肿瘤药物的深入认识,多靶点酪氨酸激酶抑制剂的抗肿瘤作用是临床研究的主要方向,本文对含喹唑啉结构的酪氨酸激酶抑制剂的研究进展作一综述。
作者 黄庄霖
机构地区 福建生物工程职业技术学院
出处 《海峡药学》 2011年第10期22-24,共3页 Strait Pharmaceutical Journal
关键词 多靶点 酪氨酸激酶抑制剂 喹唑啉 肿瘤
分类号 R979.1 [医药卫生—药品]
  • 相关文献

参考文献9

  • 1刘靖,王林,杨晓明.多靶点蛋白酪氨酸激酶抑制剂的研究进展[J].国际药学研究杂志,2009,36(3):161-171. 被引量：22
  • 2茆勇军,李海泓,李剑峰,沈敬山.蛋白酪氨酸激酶信号转导途径与抗肿瘤药物[J].药学学报,2008,43(4):323-334. 被引量：51
  • 3Lackey KE.Lessons from the drug discovery of lapatinib,a dualErbB1/2 tyrosine kinase inhibitor〔J〕. Curr Top Mel Chem . 2006
  • 4Geyer CE,Forster J,Lindquist D,et al.Lapatinib plus capecitabine forHer2-positive advanced breast cancer〔J〕. The New England Journal of Medicine . 2006
  • 5Glaxo Smith Kline.Highlights of Prescribing Information:TYKERB(lapatinb)tables〔J/OL〕. http://www.fda.gov/cder/foi/label/2007/0220591bl.pdf .
  • 6Lee D.PhaseⅡdata with ZD6474,a small-molecule kinase inhibtor of epidermal growth factor receptor and vascular endothelial growth factor receptor,in previously treated advanced non-small-cell lung cancer. Clinical Lung Cancer Journal . 2005
  • 7S Campos,O Hamid,MV Seiden.Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. Journal of Clinical Oncology . 2005
  • 8Burris HAIII,Stoniolo AM,Overmoney EA, et al.A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GM572016) in combination with trastuzumab. Breast Cancer Research and Treatment . 2004
  • 9RYAN A J.ZD64742a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. British Journal of Cancer . 2005

二级参考文献84

  • 1Jimeno A,Hidalgo M.Multitargeted therapy:can promiscuity be praised in an era of political correctness?[J].Crit Rev Oncol Hematol,2006,59(2):150-158.
  • 2De Jonge MJ,Verweij J.Multiple targeted tyrosine kinase inhibition in the clinic:all for one or one for all?[J].Eur J Cancer,2006,42(10):1351-1356.
  • 3Keith CT,Borisy AA,Stockwell BR.Multicomponent therapeutics for networked systems[J].Nat Rev Drug Discov,2005,4(1):71-78.
  • 4Arora A,Scholar EM.Role of tyrosine kinase inhibitors in cancer therapy[J].J Pharmacol Exp Ther,2005,315(3):971-979.
  • 5Blume-Jensen P,Hunter T.Oncogenic kinase signalling[J].Nature,2001,411(6835):355-365.
  • 6Konecny GE,Pegram MD,Venkatesan N,et al.Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells[J].Cancer Res,2006,66(3):1630-1639.
  • 7Burris HA,Hurwitz HI,Dees EC,et al.Phase Ⅰ safety,pharmacokinetics,and clinical activity study of lapatinib (GW572016),a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases,in heavily pretreated patients with metastatic carcinomas[J].J Clin Oncol,2005,23(23):5305-5313.
  • 8Hanrahan EO,Heymach JV.Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer[J].Clin Cancer Res,2007,13(15):4617-4622.
  • 9Arnold AM,Seymour L,Smylie M,et al.Phase Ⅱ study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy:National Cancer Institute of Canada Clinical Trials Group Study BR.20[J].J Clin Oncol,2007,25(27):4278-4284.
  • 10Eskens FA,Mom CH,Planting AS,et al.A phase Ⅰ dose escalation study of BIBW 2992,an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on,2-week off schedule in patients with advanced solid tumours[J].Br J Cancer,2008,98(1):80-85.

共引文献68

同被引文献24

引证文献2

海峡药学
2011年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部